Dutch biotech company Mucosis B.V. has promoted Thomas Johnston, the company’s Chief Business Officer since May 2011, as CEO, replacing Govert Schouten. Prior to joining Mucosis, which is developing intranasal vaccines based on its Mimopath platform, Johnston was VP of Strategy at Novavax.
Mucosis Chairman of the Board John Lambert said, “Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team. He has played a lead role in the ongoing rollout of our Mimopath platform licensing initiative and the development of our overall strategies for continued growth. Given Tom’s substantial commercial experience and familiarity with the company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialization of the Mimopath platform including our RSV vaccine candidate.”
Johnston said, “I am honored to be given this opportunity to take on the role of CEO of Mucosis during this exciting time in the company’s history. Over the past year, our team has completed a clinical proof of concept study in human influenza for the Mimopath platform while also advancing our lead vaccine program for the prevention of RSV into pre-clinical studies. These and other recent accomplishments position us very well in the biotech marketplace and I am confident that we will be able to execute on our plan to deliver sustainable results and drive long-term value for our shareholders.”
Read the Mucosis press release.
